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Systematic reviews and meta-analyses are increasingly
popular study designs in clinical research. A systematic
review is a summary of the medical literature that uses
explicit and reproducible methods for searching the
literature and critical appraisal of individual studies; in
contrast, a meta-analysis is a mathematical synthesis of the
results of these individual studies. These study designs can
be useful tools for summarizing the increasing amount of
knowledge that is gained from scientific papers on a certain
topic. In addition, combining individual studies in a meta-
analysis increases statistical power, resulting in more precise
effect estimates. Although the specific methodology of
systematic reviews includes steps to minimize bias in all
stages of the process, investigators should be aware of
potential biases such as poor quality of included studies,
heterogeneity between studies, and the presence of
publication and outcome reporting bias. This paper explains
how systematic reviews and meta-analyses should be
performed and how to interpret and implement their results.
In addition, we discuss when meta-analyses are useful and
when they are not.
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QUORUM statement
Is treatment with a new calcium-free phosphate binder
associated with better outcomes than treatment with a
calcium-containing phosphate binder? Is echocardiography
still the best method to diagnose left ventricle hypertrophy?
And is a high body mass index really associated with a lower
mortality risk in dialysis patients? If an investigator would try
to answer these questions based on articles in the literature, it
is likely that he or she would find several articles with
dissimilar or even conflicting results. To help identify which
treatments are effective, which are not, and which are even
harmful, results from similar studies can be brought together
in systematic reviews. A systematic review is a review of the
medical literature using explicit and reproducible methods
for literature search and appraisal of individual studies;
whereas a meta-analysis is a mathematical synthesis of the
results of these individual studies. Systematic reviews and
meta-analyses are performed in order to summarize the
increasing amount of knowledge that is gained from scientific
papers, and to provide an overview of the ‘state of the art’ of
a certain topic.
The number of published systematic reviews and meta-
analyses has increased substantially in the last decade and also
within the field of nephrology more and more of these
studies are published.1 A PubMed search in English-language
literature using the search terms ‘meta-analysis’ and ‘kidney’
yielded a total of 106 publications between 1995 and 2000,
while this number had increased to 273 between 2000 and
2005, and to 228 after 2005.
In this study we explain why systematic reviews and meta-
analyses are applied, how they should be performed, and
where to find them. We also discuss the reporting and the
interpretation of their results and instances where they are
useful and when they are not.
WHY SYSTEMATIC REVIEWS AND META-ANALYSES?
Systematic reviews aim to provide a systematic overview of
study results on a certain subject by including all available
information from similar individual studies that, viewed
separately, may be conductive to inconclusive results due to a
relatively small sample size. By combining those individual
studies in a meta-analysis, the study power can be increased
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substantially, resulting in effect estimates that are more
precise.
The predefined and explicit methodology of a systematic
review includes steps to minimize bias in all parts of the
process: identifying relevant studies, selecting them for
inclusion, and collecting and combining their data. The
articles that result from this process can be helpful for clinical
decisions, and they may also serve as the foundation for
evidence-based practice guidelines, economic evaluations,
and future research agendas.
Example 1
Clinical trials in the general population have demonstrated
beneficial effects of treatment of dyslipidemia with statins.
However, reports of effects in patients with chronic kidney
disease (CKD) have been conflicting. Therefore, Strippoli
et al.2 performed a meta-analysis of 50 Randomized
Controlled Trials (RCTs) on the effects of statins on several
outcomes in patients with different stages of CKD. They
concluded that when compared with placebo or no
treatment, statins significantly reduce lipid concentrations,
like total cholesterol (weighted mean reduction 42.28mg/
dl; 95% confidence interval (CI): 47.25 to 37.32) and fatal
cardiovascular end points (relative risk: 0.81, 95% CI:
0.73–0.90), in CKD patients irrespective of the stage of
disease.2
In this study we focus on meta-analyses. However, each
well-performed meta-analysis should be preceded by a
systematic review of the literature and we, therefore, first
describe how one should systematically search and review the
available literature on a specific topic.
THE STRUCTURE OF A SYSTEMATIC REVIEW
Research question
Every systematic review is based on a clinical problem, which
can be translated to one or more relevant research questions.
To formulate a research question, one should consider how
the following four categories apply to the research topic:
K Patient, population, or problem (P): Which character-
istics, like the target clinical condition, ethnicity, and age
group, define the patients or population?
K Intervention (I): Which intervention or exposure (e.g.,
form of treatment, diagnostic test, or educational pro-
gramme) is applied to the patient/population/problem?
K Comparison or control intervention (C): Is there an
alternative to the main intervention, for example,
treatment with placebo? This category is only applicable
in studies with a control group.
K Outcomes or effects (O): Which outcomes or effects
relating to the intervention, for example, side effects,
morbidity, quality of life, cost-effectiveness, are studied?
These categories together form the PICO model, an
evidence-based model for formulating a clinical question.3 If
this model is not appropriate for the research topic, it is in
some cases possible to adapt the PICO headings to fit the
type of research one is undertaking. In addition, there are
alternatives available such as ECLIPSE.4 An example of a
well-defined research question, derived from the meta-
analysis of Strippoli et al.,2 is: ‘In patients with different
stages of kidney disease (P) what are the effects of statins (I)
versus placebo or no treatment (C), on lipid concentrations
and mortality (O)?’
Literature search
Based on the defined PICO, a comprehensive search of the
literature can be performed. In most cases, a search term based
on a description of the patients and the intervention is sufficient.
If necessary, a description of the control group can be added to
the search term. Literature can be found through several
databases, such as MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials (CENTRAL, through the
Cochrane Library). The latter includes details of published
articles of clinical trials taken from bibliographic databases and
other sources. MEDLINE is freely available on the internet and
searchable via PubMed, whereas the other data sets require paid
subscription. However, particularly for search strategies related
to drug treatment, searching only PubMed may be insufficient.
To perform a literature search, one can use a simple search
strategy or a more advanced approach. A distinctive feature
of MEDLINE is that the records are indexed with Medical
Subject Headings (MeSH), which provides a consistent way
to retrieve information that may use different terminology
for the same concepts.5
Study selection
A comprehensive literature search in different databases
usually yields a large amount of articles that possibly answer
the PICO research question. From this list of articles, relevant
articles should be selected based on predefined inclusion and
exclusion criteria, regardless of their results or quality. For
reproducibility it is important to report the applied search
strategy and its yield in detail in the methods and results
sections of the systematic review. In addition, a flow diagram,
as shown in Figure 1, can be used to summarize this process.
Critical appraisal of methodological study quality
The validity of a systematic review is strongly dependent on
the risk of bias within the original studies. The next step is
therefore to assess the (methodological) quality of the included
articles. This critical appraisal should preferably be performed
by two persons, independent of each other, to guarantee
objectivity and to avoid errors. In case of disagreement
between them, discrepancies should be resolved by discussion
or by consulting an independent third reviewer. Several
checklists for the appraisal of study quality are available.6
Data extraction
From the selected studies, one needs to extract data. Also
data extraction should be performed by two persons
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independently, because results from the original studies could
be interpreted differently. An overview of the extracted data
should be presented in a table in the results section of the
systematic review.
Data analysis
When the included studies are sufficiently similar (homo-
geneous), a quantitative summary of an overall average
effect can be presented; this is called statistical pooling or
meta-analysis. In general, this calculation applies weight
factors based on the sample size and the number of events in
the studies. As a result, large studies and those with a lot
of events get more weight than smaller studies or studies
with fewer events. The statistical pooling can be performed
using the software package Review Manager (RevMan),
which can be obtained free of cost through the Cochrane
Collaboration.7 In addition, several statistical software
packages such as SAS and S-Plus can be used. The results
of a meta-analysis can be presented in a forest plot. These
plots usually present the effect estimates of all individual
studies as squares with 95% CIs, and the pooled effect
estimate of all studies combined as a diamond with 95% CI.
An example of a forest plot is shown in Figure 2.
Many systematic reviews summarize both qualitative and
quantitative results. However, a meta-analysis might be
impossible if the clinical or methodological features of the
studies are too different for their results to be averaged.
Conversely, a meta-analysis can also be performed without a
systematic approach, simply by combining the results from
more than one trial. However, although such a meta-analysis
will provide a more precise estimate of the effect than an
analysis of any one of the component trials, it might be
subject to biases that arise from the (non-systematic) study
selection process, and therefore produce a misleading result.
We, therefore, discourage performing meta-analysis without
systematic review.
Conclusions and recommendations
Finally, based on the results of the data analysis the (clinical)
research question can be answered. When data appears
insufficient or of insufficient quality, recommendations for
future research can be made.
TYPES OF META-ANALYSES: NOT ONLY OF RCTS
Meta-analyses can treat virtually every topic and every
research domain (therapy, prevention, harm, etiology, or
diagnosis). However, most of them focus on the effects of
therapy or prevention, for example, on the effects of different
immunosuppressive agents in renal transplant recipients.8
Such meta-analyses are usually based on RCTs because they
are more likely to provide unbiased information than other
study designs.9,10 Also the aforementioned meta-analysis by
Strippoli et al.2 (section Example 1) was based on 50 RCTs.
These RCTs study the effects of statins in CKD patients. The
investigators found that compared with placebo or no
treatment, statins significantly reduce lipid concentrations,
like total cholesterol (weighted mean reduction 42.28mg/dl;
95% CI: 47.25 to 37.32) and fatal and non-fatal car-
diovascular end points (relative risks: 0.81, 95% CI: 0.73–0.90
and 0.78, 95% CI: 0.73–0.84, respectively), irrespective of
the stage of CKD.2 Of course, for clinical decision, making
other considerations like side effects and cost of treatment
may also apply.
Also, meta-analyses on diagnostic testing are performed
regularly, for example, on the value of ultrasound monitoring
to detect access stenosis in hemodialysis patients.11 In
addition, meta-analyses are common in the areas of
prognosis, etiology, and adverse effects, for example, on the
association between late referral to a nephrologist and
mortality in CKD patients.12 In these meta-analyses,
individual studies with other designs, such as case–control
or cohort studies, can be included.
Medline:
  Pre-dialysis (n=146)
  Dialysis (n=32)
  Transplant (n=68)
Embase:
  Pre-dialysis (n=367)
  Dialysis (n=67)
  Transplant (n=118)
Renal health library:
  Pre-dialysis (n=38)
  Dialysis (n=14)
  Transplant (n=19)
Excluded (n=801):
  Search overlap (n=104)
  Non-randomized trials,
  or reviews (n=693)
  Duration <8 weeks (n=4)
Included in systematic review
  (n=50 trials, 54 comparisons)
  30 144 patients
  Pre-dialysis (n=26)
  Dialysis (n=11)
  Transplant (n=17)
No of trials by outcome:
  All-cause mortality (44 trials, 23,665 patients)
  Cardiovascular mortality (43 trials, 23,266 patients)
  Non-fatal cardiovascular events (8 trials, 22,863 patients)
  Lipid concentration (42 trials, 6390 patients)
  Acute allograft rejection (5 trials, 639 patients)
  24-h urinary protein excretion (6 trials, 311 patients)
  Creatinine clearance (11 trials, 548 patients)
  Elevated liver function tests (26 trials, 6726 patients)
  Rhabdomyolysis (29 trials, 6829 patients)
  Withdrawal owing to adverse events (20 trials, 4887 patients)
Full-text analysis (n=68):
  Pre-dialysis (n=22)
  Dialysis (n=16)
  Transplant (n=30) Excluded (n=16):
  Duplicate reports
  Duration <8 weeks
  Non-randomized trials
Overall result of database searches (n=869)
Figure 1 | Flow chart showing number of citations retrieved by
individual searches and number of trials included in review
on the effects of statins in patients with chronic kidney
disease. Example reproduced from Strippoli et al.2 with
permission from BMJ Publishing Group Ltd.
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Example 2
As obesity is closely related to the most common causes of
kidney disease, diabetes mellitus type II and hypertension,
Wang et al.13 recently published a meta-analysis of epide-
miological studies on the association between obesity
and kidney disease in the general population. The authors
retrieved 25 cohorts, three cross-sectional studies, and 19
case–control studies that met their inclusion criteria. Based
on the results of the cohort studies, they concluded that
compared with normal-weight individuals, obese individuals
were at higher risk to develop kidney disease (relative risk:
1.83; 95% CI: 1.78–2.07).
REPORTING META-ANALYSES
In 1999, the Quality of Reporting of Meta-Analyses (QUOR-
UM) statement was published to improve the quality of
reporting meta-analyses, particularly of RCTs.14 This statement
includes a checklist, which describes the preferred way to
present the Abstract, Introduction, Methods, Results, and
Discussion sections of a report of a meta-analysis. Second,
QUORUM requires authors to present a flow diagram
providing information about the number of RCTs identified,
included, and excluded, and the reasons for exclusion.
An example of such a flow diagram derived from the study
by Strippoli et al.2 is provided in Figure 1. In addition,
assessment of the methodological quality of systematic reviews
can be performed by using the AMSTAR measurement tool.15
CHALLENGES IN META-ANALYSES
Low study quality
The quality of the studies can be assessed using a checklist for
study quality, as mentioned before. However, the assessment
of study quality can be problematic because essential details
on study quality are often not reported or difficult to
ascertain. Therefore, in 2001 the Consolidated Standards of
Reporting Trials (CONSORT) statement was introduced.16,17
The statement helps authors to improve the reporting of an
RCT, thereby enabling readers to understand a trial’s conduct
and to assess the validity of its results.
Example 3
Although commonly used, vitamin D compounds have
unclear benefits and potential harms for CKD patients.
For that reason, Palmer et al.18 performed a systematic review
and meta-analysis on the effect of vitamin D therapy
on biochemical markers of mineral metabolism and
0.20.1 0.5 21 5 10
Study or subcategory
Pre-dialysis patients
Rayner 1995 0/42 2/45
PPP 2004 436/8376 527/8448
PREVEND IT 2004 4/433 4/431
Lemos 2005 3/150 3/160
Subtotal (95% Cl)
Total events: 423 (statin), 536 (placebo)
Test for heterogeneity: χ2=0.96, df=3, P=0.81, I2=0%
Test for overall effect: z=3.58, P<0.001
Dialysis patients
PERFECT study 1997
Lins 2004
4D trial 2005
Subtotal (95% Cl)
Total events: 121 (statin), 151 (placebo)
Test for heterogeneity: χ2=0.80, df=2, P=0.67, I2=0%
Test for overall effect: z=1.76, P=0.08
Transplant patients
Katznelson 1996
Kasiske 2001
Holdaas 2003
Subtotal (95% Cl)
Total events: 38 (statin), 55 (placebo)
Test for heterogeneity: χ2=1.86, df=2, P=0.39, I2=0%
Test for overall effect: z=1.83, P =0.07
Mixed population (dialysis and pre-dialysis patients)
Stegmayr 2005
Subtotal (95% Cl)
Total events: 23 (statin), 17 (placebo)
Test for heterogeneity: not applicable
Test for overall effect: z=1.26, P =0.21
Total (95% Cl)
Total events: 605 (statin), 759 (placebo)
Test for heterogeneity: χ2=8.53, df=10, P =0.58, I2=0%
Test for overall effect: z=4.00,  P <0.001
10894 10993
70 73
23/70 17/73
1127 1128
36/1050 54/1052
2/53 0/52
0/24 1/24
696 708
121/619 149/636
0/23 1/19
0/54 1/53
9001 9084
Statin
n /N
Placebo
n /N
Relative risk
(random) (95% Cl)
Weight
(%)
Relative risk
(random) (95% Cl) Year
0.11 0.21 (0.01 to 4.33) 1995
66.07 0.80 (0.70 to 0.90) 2004
0.54 1.00 (0.25 to 3.95) 2004
0.41 1.07 (0.22 to 5.20) 2005
67.14 0.80 (0.70 to 0.90)
0.10  0.33 (0.01 to 7.86) 1997
0.10 0.28 (0.01 to 6.45) 2004
22.78 0.83 (0.67 to 1.03) 2005
22.98 0.83 (0.67 to 1.02)
0.10  0.33 (0.01 to 7.80) 1996
0.11 4.91 (0.24 to 99.82) 2001
6.05 0.67 (0.44 to 1.01) 2003
6.27 0.68 (0.46 to 1.03)
3.61 1.41 (0.83 to 2.41) 2005
3.61 1.41 (0.83 to 2.41)
100.00 0.81 (0.73 to 0.90)
Favors
statin
Favors
placebo
Figure 2 | Forest plot showing the effects of statins as compared with placebo or no treatment, on cardiovascular mortality in
pre-dialysis, dialysis, and transplant patients. Effects in individual trials are depicted as squares with 95% CIs. Effects of meta-analyses
are depicted as diamonds. Example reproduced from Strippoli et al.2 with permission from BMJ Publishing Group Ltd.
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cardiovascular outcomes in CKD patients. The authors
assessed trial quality of the 76 RCTs eligible for inclusion.
It appeared that important information was poorly reported.
For example, allocation concealment was adequate in 17
(22%) trials, inadequate in eight trials (11%), and not
reported in all others (67%).
In systematic reviews, all studies that meet the inclusion
criteria, also those with poor quality, should be included. In
meta-analyses, inclusion of reports of low-quality RCTs may
be seriously misleading because they are at risk of bias.
Therefore, one might consider ruling out those reports of
low-quality studies from the analysis. An alternative is to
report results of the meta-analysis stratified for study quality.
Heterogeneity
A criticism of meta-analyses is that some ‘combine apples
with oranges’; for instance, studies with different dose
schedules, follow-up, types of participants, or modes of
treatment. If studies are clinically (or methodologically) too
diverse, the results of a meta-analysis may be meaningless. In
addition to this clinical heterogeneity, variability in the effects
being evaluated in the different studies is known as statisti-
cal heterogeneity. Tests for statistical heterogeneity, like
Cochran’s Q-statistic and the I2 statistic, are commonly used
in meta-analysis to determine whether there are genuine
differences underlying the results of the studies, or whether
the variation in findings is compatible with chance alone.19,20
An advantage of I2 is that it can be calculated and compared
across meta-analyses with different sizes and types. When
severe heterogeneity (I2460%) is detected, the meta-analysis
should be aborted. In case the statistical heterogeneity is
moderate, that is, between 30–60%, a random-effects model
can be applied.19,21 Random-effects models assume that no
single true treatment effect exists, but that each study has a
different true effect.
In the meta-analysis on the effects of statins (section
Example 1), outcomes were studied for groups of pre-dialy-
sis, dialysis, and transplant patients. In these three groups, the
investigators found pooled relative risks for all-cause morta-
lity of 0.81 (95% CI: 0.74–0.89), 0.95 (95% CI: 0.85–1.06),
and 1.30 (95% CI: 0.54–3.12), respectively. The overall pooled
effect estimate for these groups combined was 0.92 (95% CI:
0.82–1.03), indicating that there was no significant reduction
in all-cause mortality risk associated with statins in CKD.
Heterogeneity for the endpoint all-cause mortality was not
statistically significant (I2¼ 25,2%, P-value for interaction
between the three patient groups¼ 0.12), but may still exist.
Studies using different types of statins were combined. This
could lead to heterogeneity, especially because statins are a
class of drugs with known pleiotropic effects.
In their meta-analysis on the effect of vitamin D
compounds in CKD patients, Palmer et al.18 also combined
pre-dialysis with dialysis studies, and studies with pediatric
patients with those with adult patients. Furthermore,
different studies were pooled to provide results for each
endpoint because only a handful provided information on all
biochemical measures. Because pooled parathyroid hormone
results showed significant heterogeneity (I2¼ 76.3%), the
authors appropriately warned that the parathyroid hormone
conclusions should be interpreted with caution.
These examples illustrate that heterogeneity is a sub-
stantial problem in meta-analyses and deserves comprehen-
sive analysis and description.
Publication bias and outcome reporting bias
Although publication bias has been discussed in this
epidemiology series before by Tripepi et al.,22 it is so tightly
related to the subject of this study that it is revisited here.
One can imagine that it is not only important that each
published study is unbiased, but also that the published
studies constitute an unbiased sample of all studies
performed on the subject. When these assumptions are not
met, a meta-analysis will give a distorted view of the
exposure–outcome association of interest. This phenomenon
is called publication bias and it occurs because studies
reporting statistically significant and positive effects of a
treatment are more likely to be submitted and published than
work with non-significant or negative results.22,23 Also,
statistically significant outcomes are more likely to be fully
reported as compared with non-significant outcomes.24 As a
result, publication bias results in overestimation of treatment
effects or risk-factor associations, leading to inappropriate
decisions of patient management or health policy.23,25
In any meta-analysis, it is therefore important to assess
publication bias. The simplest and most commonly used
method to detect such bias is the funnel plot (see Figure 3).25
Favors frusemide
0.001
0.0
0.4
0.8
1.2
1.6
0.01 0.1 1 10 100 1000
Favors control
Relative risk (fixed effect)
s.
e.
 
(lo
g r
ela
tiv
e
 r
is
k)
Figure 3 | Funnel plot of the relative risk against the standard
error of the logarithm of the relative risk. The relative risk is
plotted on a logarithmic scale, so that effects of the same
magnitude but opposite direction, for example, 0.5 and 2.0, are
equidistant from 1.0. Individual trials are depicted as dots,
scattered around the neutral relative risk of 1.0. The relative risks
of mortality found in the largest studies were close to 1.0, whereas
the smaller trials provided higher relative risks. Visual examination
of the funnel plot for publication bias suggests that small
trials with negative effects may be underrepresented. Example
reproduced from Ho and co-workers26 with permission from BMJ
Publishing Group Ltd.
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In a funnel plot, the treatment effect of each individual study
is plotted against some measure of its size, like the standard
error or the overall sample size. In the absence of publication
bias, these plots should be symmetrically shaped like a funnel,
because the estimate of the effect of a treatment has a larger
variability in smaller studies compared with the variability in
larger studies. Since smaller and negative studies are less
likely to be published, trials in the bottom left-hand corner of
the plot are often absent, creating a degree of asymmetry in
the funnel.22 Other reasons for funnel plot asymmetry
besides publication bias are small-study effects, a small
number of included studies, or substantial heterogeneity
between trials.25
Example 4
Ho and co-workers performed a meta-analysis of nine RCTs
to investigate the potential beneficial and adverse effects of
frusemide to prevent or treat acute renal failure in adults.26
In this meta-analysis, small studies showing reduction of
mortality risk after frusemide treatment were absent,
indicating that publication bias was possible. The funnel
plot from this study, in which the relative risk is plotted
against the standard error of the logarithm of the relative risk,
is presented in Figure 3. It demonstrates that the relative risks
of mortality found in the largest studies were close to the
neutral relative risk of 1.0, whereas the smaller trials provided
higher relative risks. The shape of the plot indeed suggests
potential publication bias, because small studies showing
reduced mortality after frusemide treatment are missing.
However, in this example the asymmetrical shape could also
be the result of the small number of included studies. Other
examples of publication bias and funnel plots can be found in
the study by Tripepi et al.22
Publication bias can be reduced, or potentially avoided, by
including unpublished studies in the meta-analysis and by use
of prospective trial registries.27 These registries are publicly
available and provide information about the existence and
design of ongoing trials. The idea is that even if the results of a
trial are never published, one could examine trial registers to
observe that the study had taken place. In the case of published
papers, it is possible to ensure that all outcomes of interest
are reported. This could result in reducing over-optimistic
conclusions about treatment benefits.
In addition, focusing on larger studies can be an approach
to avoid publication bias, since small trials are more
susceptible to it. In case a very large trial with a significant
and relevant effect (i.e., effects far from the neutral value
of 1.0) has been published, there is no use combining the
results of that study with those of small studies, because
the overall effect estimate will be close to the effect of the
largest trial.
Keeping meta-analyses up to date
Since systematic reviews and meta-analyses exist for many
interventions, the challenge is to update them and to keep the
evidence base relevant. However, little is known about the
extent to which they require updating. A recent study showed
that 23% of a sample of 100 meta-analyses became out
of date within 2 years after their publication, and 15% within
1 year.28 Although some recent reports describe a number of
strategies and methods regarding when and how to update
systematic reviews and meta-analyses,29,30 more research is
needed to develop pragmatic and efficient methodologies for
updating these studies.
WHERE TO FIND META-ANALYSES
Almost every medical journal publishes meta-analyses
regularly. In addition, meta-analyses can be found in the
Cochrane Library. This library consists of a regularly updated
collection of evidence-based medicine databases among
which is the Cochrane Database of Systematic Reviews. This
database comprises systematic reviews, predominantly in-
cluding meta-analyses, of healthcare interventions that are
produced and disseminated by the Cochrane Collaboration.
Reviews in this database are organized by review group and
topic, such as the Cochrane Renal group. The Cochrane
Library is published on a quarterly basis and made available
both on CD-ROM and the Internet. Abstracts in the database
are freely available; however, a subscription is needed to
access full papers.
SUMMARY AND CONCLUSIONS
In summary, systematic reviews and meta-analyses are
increasingly popular study designs in clinical research and
can be useful tools to increase statistical power and to
summarize the current ‘state of the art’ of a certain topic.
Although the explicit and reproducible methodology of
systematic reviews includes steps to minimize bias in all parts
of the process, investigators should be aware of potential
biases such as poor quality of included studies, heterogeneity
between studies, and presence of publication and outcome
reporting bias.
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